|
1
|
Park JR, Eggert A and Caron H:
Neuroblastoma: Biology, prognosis, and treatment. Hematol Oncol
Clin North Am. 24:65–86. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
London WB, Castel V, Monclair T, Ambros
PF, Pearson AD, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL,
Iehara T and Matthay KK: Clinical and biologic features predictive
of survival after relapse of neuroblastoma: A report from the
International Neuroblastoma Risk Group Project. J Clin Oncol.
29:3286–3292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Castel V, Grau E, Noguera R and Martínez
F: Molecular biology of neuroblastoma. Clin Transl Oncol.
9:478–483. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
London WB, Boni L, Simon T, Berthold F,
Twist C, Schmidt ML, Castleberry RP, Matthay KK, Cohn SL and De
Bernardi B: The role of age in neuroblastoma risk stratification:
The German, Italian, and children's oncology group perspectives.
Cancer Lett. 228:257–266. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pearson AD, Pinkerton CR, Lewis LJ, Imeson
J, Ellershaw C and Machin D: European Neuroblastoma Study Group;
Children's Cancer and Leukaemia Group (CCLG formerly United Kingdom
Children's Cancer Study Group): High-dose rapid and standard
induction chemotherapy for patients aged over 1 year with stage 4
neuroblastoma: A randomised trial. Lancet Oncol. 9:247–256. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kushner BH, Kramer K, LaQuaglia MP, Modak
S and Cheung NV: Neuroblastoma in adolescents and adults: The
Memorial Sloan-Kettering experience. Med Pediatr Oncol. 41:508–515.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tang SQ, Huang DS, Wang JW, Feng C and
Yang G: Long-term effect of high dose chemotherapy combined with
stem cell transplantation on stage IV neuroblastoma in children.
Zhongguo Dang Dai Er Ke Za Zhi. 8:93–96. 2006.(In Chinese).
PubMed/NCBI
|
|
8
|
Morgenstern DA, London WB, Stephens D,
Volchenboum SL, Hero B, Di Cataldo A, Nakagawara A, Shimada H,
Ambros PF, Matthay KK, et al: Metastatic neuroblastoma confined to
distant lymph nodes (stage 4N) predicts outcome in patients with
stage 4 disease: A study from the International Neuroblastoma Risk
Group Database. J Clin Oncol. 32:1228–1235. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brodeur GM, Pritchard J, Berthold F,
Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE,
Favrot M and Hedborg F: Revisions of the international criteria for
neuroblastoma diagnosis, staging, and response to treatment. J Clin
Oncol. 11:1466–1477. 1993.PubMed/NCBI
|
|
10
|
Umehara S, Nakagawa A, Matthay KK, Lukens
JN, Seeger RC, Stram DO, Gerbing RB and Shimada H: Histopathology
defines prognostic subsets of ganglioneuroblastoma, nodular.
Cancer. 89:1150–1161. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Radner H, Blümcke I, Reifenberger G and
Wiestler OD: The new WHO classification of tumors of the nervous
system 2000. Pathology and genetics. Pathologe. 23:260–283.
2002.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Peuchmaur M: Peripheral neuroblastic
tumors: Anatomo pathological classification. Ann Pathol.
24:556–567. 2004.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Øra I and Eggert A: Progress in treatment
and risk stratification of neuroblastoma: Impact on future clinical
and basic research. Semin Cancer Biol. 21:217–228. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schwab M, Alitalo K, Klempnauer KH, Varmus
HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M and Trent J:
Amplified DNA with limited homology to myc cellular oncogene is
shared by human neuroblastoma cell lines and a neuroblastoma
tumour. Nature. 305:245–248. 1983. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Monclair T, Brodeur GM, Ambros PF, Brisse
HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK,
Nuchtern JG, et al: INRG Task Force: The International
Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force
report. J Clin Oncol. 27:298–303. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Breslow N and McCann B: Statistical
estimation of prognosis for children with neuroblastoma. Cancer
Res. 31:2098–2103. 1971.PubMed/NCBI
|
|
17
|
Sung KW, Lee SH, Yoo KH, Jung HL, Cho EJ,
Koo HH, Lee SK, Kim J, Lim DH, Suh YL and Kim DW: Tandem high-dose
chemotherapy and autologous stem cell rescue in patients over 1
year of age with stage 4 neuroblastoma. Bone Marrow Transplant.
40:37–45. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
London WB, Castleberry RP, Matthay KK,
Look AT, Seeger RC, Shimada H, Thorner P, Brodeur G, Maris JM,
Reynolds CP and Cohn SL: Evidence for an age cutoff greater than
365 days for neuroblastoma risk group stratification in the
Children's Oncology Group. J Clin Oncol. 23:6459–6465. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schmidt ML, Lal A, Seeger RC, Maris JM,
Shimada H, O'Leary M, Gerbing RB and Matthay KK: Favorable
prognosis for patients 12 to 18 months of age with stage 4
nonamplified MYCN neuroblastoma: A Children's Cancer Group Study. J
Clin Oncol. 23:6474–6480. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
George RE, London WB, Cohn SL, Maris JM,
Kretschmar C, Diller L, Brodeur GM, Castleberry RP and Look AT:
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis
in children 12 to 18 months old with disseminated neuroblamoma: A
Pediatric Oncology Group study. J Clin Oncol. 23:6466–6473. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hero B, Simon T, Spitz R, Ernestus K,
Gnekow AK, Scheel-Walter HG, Schwabe D, Schilling FH, Benz-Bohm G
and Berthold F: Localized infant neuroblastomas often show
spontaneous regression: Results of the prospective trials NB95-S
and NB97. J Clin Oncol. 26:1504–1510. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Levitt GA, Platt KA, De Byrne R, Sebire N
and Owens CM: 4S neuroblastoma: The long-term outcome. Pediatr
Blood Cancer. 43:120–125. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hsu LL, Evans AE and D'Angio GJ:
Hepatomegaly in neuroblastoma stage 4s: Criteria for treatment of
the vulnerable neonate. Med Pediatr Oncol. 27:521–528. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nickerson HJ, Matthay KK, Seeger RC,
Brodeur GM, Shimada H, Perez C, Atkinson JB, Selch M, Gerbing RB,
Stram DO and Lukens J: Favorable biology and outcome of stage IV-S
neuroblastoma with supportive care or minimal therapy: A Children's
Cancer Group Study. J Clin Oncol. 18:477–486. 2000.PubMed/NCBI
|
|
25
|
Haupt R, Garaventa A, Gambini C, Parodi S,
Cangemi G, Casale F, Viscardi E, Bianchi M, Prete A, Jenkner A, et
al: Improved survival of children with neuroblastoma between 1979
and 2005: A report of the Italian Neuroblastoma Registry. J Clin
Oncol. 28:2331–2338. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Weintraub M, Waldman E, Koplewitz B, Bloom
AI, Gross E, Freeman AI and Revel-Vilk S: A sequential treatment
algorithm for infants with stage 4s neuroblastoma and massive
hepatomegaly. Pediatr Blood Cancer. 59:182–184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Weintraub M, Bloom AI, Gross E, Revel-Vilk
S, Shahroor S, Koplewitz BZ and Freeman AI: Successful treatment of
progressive stage 4s hepatic neuroblastoma in a neonate with
intra-arterial chemoembolization. Pediatr Blood Cancer. 43:148–151.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Garaventa A, Parodi S, De Bernardi B, Dau
D, Manzitti C, Conte M, Casale F, Viscardi E, Bianchi M, D'Angelo
P, et al: Outcome of children with neuroblastoma after progression
or relapse. A retrospective study of the Italian neuroblastoma
registry. Eur J Cancer. 45:2835–2842. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lau L, Tai D, Weitzman S, Grant R,
Baruchel S and Malkin D: Factors influencing survival in children
with recurrent neuroblastoma. J Pediatr Hematol Oncol. 26:227–232.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
London WB, Frantz CN, Campbell LA, Seeger
RC, Brumback BA, Cohn SL, Matthay KK, Castleberry RP and Diller L:
Phase II randomized comparison of topotecan plus cyclophosphamide
versus topotecan alone in children with recurrent or refractory
neuroblastoma: A Children's Oncology Group study. J Clin Oncol.
28:3808–3815. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ashraf K, Shaikh F, Gibson P, Baruchel S
and Irwin MS: Treatment with topotecan plus cyclophosphamide in
children with first relapse of neuroblastoma. Pediatr Blood Cancer.
60:1636–1641. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maris JM: Recent advances in
neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sałacińska-Łoś E, Kobos J and Taran K:
Estimation of diagnostic value of chosen markers of neural
differentiation in neuroblastoma group of tumors and pPNETs. Pol J
Pathol. 59:195–199. 2008.PubMed/NCBI
|
|
34
|
George RE, Variend S, Cullinane C,
Cotterill SJ, McGuckin AG, Ellershaw C, Lunec J and Pearson AD:
United Kingdom Children Cancer Study Group: Relationship between
histopathological features, MYCN amplification, and prognosis: A
UKCCSG study. United Kingdom Children Cancer Study Group. Med
Pediatr Oncol. 36:169–176. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ambros IM, Hata J, Joshi VV, Roald B,
Dehner LP, Tüchler H, Pötschger U and Shimada H: Morphologic
features of neuroblastoma (Schwannian stroma-poor tumors) in
clinically favorable and unfavorable groups. Cancer. 94:1574–1583.
2002. View Article : Google Scholar : PubMed/NCBI
|
